RxDoctor Payments Data

David Schreibman, MD

Interventional Cardiology · Sarasota, FLNPI 1659324044

Payments from drug & device makers

$3,228in general payments, 2019–2025

Across 188 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$482
  • Novartis$398
  • Pfizer$352
  • Sanofi-aventis U.S. LLC$212
  • Johnson & Johnson$193
  • Regeneron Healthcare Solutions, Inc.$191
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,20699%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,228 in reported general payments places this provider in the 20th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,185,998
Medicare patients
3,610
Services billed
9,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban877$1,188,917
VyndamaxTafamidis16$582,980
EntrestoSacubitril/Valsartan298$372,567
Repatha SureclickEvolocumab308$259,312
VyndaqelTafamidis Meglumine11$239,249
FarxigaDapagliflozin Propanediol108$117,474
XareltoRivaroxaban62$76,605
Praluent PenAlirocumab68$47,453
MultaqDronedarone Hcl20$44,095
JardianceEmpagliflozin38$43,613
VascepaIcosapent Ethyl37$27,029
BrilintaTicagrelor18$17,109
Ezetimibe447$13,458
Metoprolol Succinate681$9,555
Atorvastatin Calcium518$6,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax, Vyndaqel$352$2,011,146904 claims
NovartisEntresto$398$372,567298 claims
AstraZenecaFarxiga, Brilinta$18$134,584126 claims
Johnson & JohnsonXarelto$193$76,60562 claims
Sanofi-aventis U.S. LLCMultaq$212$44,09520 claims
Boehringer IngelheimJardiance$83$43,61338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →